A detailed history of Zurcher Kantonalbank (Zurich Cantonalbank) transactions in Collegium Pharmaceutical, Inc stock. As of the latest transaction made, Zurcher Kantonalbank (Zurich Cantonalbank) holds 9,734 shares of COLL stock, worth $282,870. This represents 0.0% of its overall portfolio holdings.

Number of Shares
9,734
Previous 9,734 -0.0%
Holding current value
$282,870
Previous $376,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

SELL
$31.4 - $39.07 $345 - $429
-11 Reduced 0.11%
9,734 $376,000
Q2 2024

Jul 29, 2024

BUY
$31.36 - $39.99 $30,074 - $38,350
959 Added 10.92%
9,745 $313,000
Q1 2024

Apr 25, 2024

SELL
$31.23 - $40.91 $1,717 - $2,250
-55 Reduced 0.62%
8,786 $341,000
Q4 2023

Jan 30, 2024

BUY
$21.16 - $30.8 $41,621 - $60,583
1,967 Added 28.62%
8,841 $272,000
Q3 2023

Oct 25, 2023

SELL
$21.23 - $24.28 $4,628 - $5,293
-218 Reduced 3.07%
6,874 $153,000
Q2 2023

Aug 07, 2023

SELL
$21.06 - $24.0 $4,527 - $5,160
-215 Reduced 2.94%
7,092 $152,000
Q1 2023

May 08, 2023

BUY
$23.0 - $29.88 $25,231 - $32,778
1,097 Added 17.67%
7,307 $175,000
Q4 2022

Feb 01, 2023

BUY
$16.14 - $23.55 $26,259 - $38,315
1,627 Added 35.5%
6,210 $144,000
Q2 2020

Jul 28, 2020

BUY
$15.49 - $23.51 $38,988 - $59,174
2,517 Added 121.83%
4,583 $80,000
Q1 2020

May 06, 2020

BUY
$13.89 - $25.45 $16,001 - $29,318
1,152 Added 126.04%
2,066 $34,000
Q1 2019

Apr 29, 2019

SELL
$13.58 - $18.72 $14,163 - $19,524
-1,043 Reduced 53.3%
914 $14,000
Q2 2018

Aug 06, 2018

SELL
$21.79 - $28.29 $23,903 - $31,034
-1,097 Reduced 35.92%
1,957 $47,000
Q4 2017

Jan 31, 2018

BUY
$9.3 - $19.14 $28,402 - $58,453
3,054
3,054 $56,000

Others Institutions Holding COLL

About COLLEGIUM PHARMACEUTICAL, INC


  • Ticker COLL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 34,126,200
  • Market Cap $992M
  • Description
  • Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ...
More about COLL
Track This Portfolio

Track Zurcher Kantonalbank (Zurich Cantonalbank) Portfolio

Follow Zurcher Kantonalbank (Zurich Cantonalbank) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Zurcher Kantonalbank (Zurich Cantonalbank), based on Form 13F filings with the SEC.

News

Stay updated on Zurcher Kantonalbank (Zurich Cantonalbank) with notifications on news.